nd standard biotools Search Results


cleaved parp  (fluidigm)
94
fluidigm cleaved parp
Cleaved Parp, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cleaved parp/product/fluidigm
Average 94 stars, based on 1 article reviews
cleaved parp - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
cleaved caspase 3  (fluidigm)
94
fluidigm cleaved caspase 3
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Cleaved Caspase 3, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cleaved caspase 3/product/fluidigm
Average 94 stars, based on 1 article reviews
cleaved caspase 3 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
pan-leukocytes  (fluidigm)
90
fluidigm pan-leukocytes
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Pan Leukocytes, supplied by fluidigm, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan-leukocytes/product/fluidigm
Average 90 stars, based on 1 article reviews
pan-leukocytes - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
biotools 3149002b 150 nd ly6c hk1  (fluidigm)
95
fluidigm biotools 3149002b 150 nd ly6c hk1
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Biotools 3149002b 150 Nd Ly6c Hk1, supplied by fluidigm, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotools 3149002b 150 nd ly6c hk1/product/fluidigm
Average 95 stars, based on 1 article reviews
biotools 3149002b 150 nd ly6c hk1 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
3141017d vimentin d21h3 nd 143  (fluidigm)
95
fluidigm 3141017d vimentin d21h3 nd 143
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
3141017d Vimentin D21h3 Nd 143, supplied by fluidigm, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3141017d vimentin d21h3 nd 143/product/fluidigm
Average 95 stars, based on 1 article reviews
3141017d vimentin d21h3 nd 143 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
3143027d cd68 fa 11 nd 145  (fluidigm)
95
fluidigm 3143027d cd68 fa 11 nd 145
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
3143027d Cd68 Fa 11 Nd 145, supplied by fluidigm, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3143027d cd68 fa 11 nd 145/product/fluidigm
Average 95 stars, based on 1 article reviews
3143027d cd68 fa 11 nd 145 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
nd standard biotools  (fluidigm)
94
fluidigm nd standard biotools
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Nd Standard Biotools, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nd standard biotools/product/fluidigm
Average 94 stars, based on 1 article reviews
nd standard biotools - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
biotools 3147003b 148 nd cd11b m1  (fluidigm)
93
fluidigm biotools 3147003b 148 nd cd11b m1
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Biotools 3147003b 148 Nd Cd11b M1, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotools 3147003b 148 nd cd11b m1/product/fluidigm
Average 93 stars, based on 1 article reviews
biotools 3147003b 148 nd cd11b m1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
anti-mouse cd8a (53-6.7)- 146 nd  (fluidigm)
90
fluidigm anti-mouse cd8a (53-6.7)- 146 nd
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Anti Mouse Cd8a (53 6.7) 146 Nd, supplied by fluidigm, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mouse cd8a (53-6.7)- 146 nd/product/fluidigm
Average 90 stars, based on 1 article reviews
anti-mouse cd8a (53-6.7)- 146 nd - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
monocytes nd 148 cd16 3g8 s standard biotools 3148004b ab 3665424  (fluidigm)
95
fluidigm monocytes nd 148 cd16 3g8 s standard biotools 3148004b ab 3665424
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Monocytes Nd 148 Cd16 3g8 S Standard Biotools 3148004b Ab 3665424, supplied by fluidigm, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monocytes nd 148 cd16 3g8 s standard biotools 3148004b ab 3665424/product/fluidigm
Average 95 stars, based on 1 article reviews
monocytes nd 148 cd16 3g8 s standard biotools 3148004b ab 3665424 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
3145002b 146 nd f4 80 bm8 100  (fluidigm)
95
fluidigm 3145002b 146 nd f4 80 bm8 100
( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved <t>caspase-3</t> in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.
3145002b 146 Nd F4 80 Bm8 100, supplied by fluidigm, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3145002b 146 nd f4 80 bm8 100/product/fluidigm
Average 95 stars, based on 1 article reviews
3145002b 146 nd f4 80 bm8 100 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved caspase-3 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Journal: Science Advances

Article Title: Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias

doi: 10.1126/sciadv.adh1436

Figure Lengend Snippet: ( A ) Relative quantitation (RQ) values by quantitative PCR for CDKN1A and MDM2 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for the indicated time points. ( B ) Pathway analyses comparing Mil versus Mil + Sel and Sel versus Mil + Sel in RNA-seq in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 12 hours. The top up-regulated and down-regulated pathways are indicated by red and blue arrows, respectively. NES, normalized enrichment score. ( C ) Volcano plots [beta score (magnitude) and q values (significance, −log 10 scale)] from differential gene expression profiles in RNA-seq from OCI-AML3 cells DMSO versus Mil (left), Sel (middle), and versus Mil + Sel (right). The top 10 up-regulated TP53 targets and down-regulated MYC targets are indicated with red and blue colors, respectively. The remaining genes are indicated in gray. ( D ) Cell cycle analyses using multiparameter flow cytometry with Ki-67, p21, and cleaved caspase-3 in OCI-AML3 cells treated with Mil, Sel, or Mil + Sel for 24 hours. Caspase-3–negative cells were gated for EdU, Ki-67, and p21 panels. ( E and F ) Change in the percentages of cells in S (E) and M (F) phases in OCI-AML3 cells in indicated treatments. ( G ) The percentages of “p21 high” OCI-AML3 cells [rectangles shown in the third row of (D)] in indicated treatments. ( H ) Change of cell percentages of cleaved caspase-3–positive OCI-AML3 cells [rectangles shown in the fourth row of (D)] in indicated treatments for G 1 (2N) and G 2 -M (4N) phases. A Mil and Sel concentration of 160 nM was used. ** P < 0.01; *** P < 0.001; **** P < 0.0001.

Article Snippet: We used the following antibodies: BCL-X L (141 Pr, clone 54H6; CST, 2764BF), cleaved caspase-3 (142 Nd, clone D3E9;Standard BioTools, 3142004A), BCL2 (144 Nd, clone 100; BioLegend, 658702), CD123 (145 Nd, clone 7G3; BD Biosciences, 554527), CD34 (148 Nd, clone 581; BD Biosciences, 555820); LC3B (150 Nd, clone D11; CST 3868 custom), p21 (153 Eu, 12D1; CST 2947BF), CD45 (154 Sm, clone HI30; Standard BioTools 3154001B), CD33 (158 Gd, clone WM53; Standard BioTools, 3158001B), ATF4 (160 Gd, polyclonal; ProteinTech 10835-1-AP), p53 (165 Ho, clone 184721; R&D, MAB1355), CD44 (166 Er, clone BJ18; Standard BioTools, 3166001B), CD38 (168 Er, HIT2; BioLegend, 303502), CXCR4 (172 Yb, clone 12G5; BioLegend, 306502), BAX (173 Yb, clone 2D2; BioLegend, 633602), Ki-67 (175 Lu, clone Ki-67; BioLegend, 350502), and MCL1 (176 Yb, clone D2W9E; CST, 94296BF).

Techniques: Quantitation Assay, Real-time Polymerase Chain Reaction, RNA Sequencing Assay, Expressing, Flow Cytometry, Concentration Assay